Free Trial

InflaRx (IFRX) Competitors

InflaRx logo
$0.88 +0.06 (+6.82%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$0.86 -0.01 (-1.47%)
As of 08:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IFRX vs. EDIT, DSGN, TVRD, SCPH, MDWD, KOD, ACIU, CRGX, LRMR, and CTMX

Should you be buying InflaRx stock or one of its competitors? The main competitors of InflaRx include Editas Medicine (EDIT), Design Therapeutics (DSGN), Tvardi Therapeutics (TVRD), scPharmaceuticals (SCPH), MediWound (MDWD), Kodiak Sciences (KOD), AC Immune (ACIU), CARGO Therapeutics (CRGX), Larimar Therapeutics (LRMR), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical products" industry.

InflaRx vs. Its Competitors

InflaRx (NASDAQ:IFRX) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

InflaRx has a net margin of 0.00% compared to Editas Medicine's net margin of -701.06%. InflaRx's return on equity of -64.17% beat Editas Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
InflaRxN/A -64.17% -53.39%
Editas Medicine -701.06%-139.24%-63.87%

InflaRx has higher earnings, but lower revenue than Editas Medicine. InflaRx is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InflaRx$180K326.66-$49.85M-$0.82-1.07
Editas Medicine$32.31M7.41-$237.09M-$3.04-0.94

In the previous week, InflaRx and InflaRx both had 1 articles in the media. Editas Medicine's average media sentiment score of 0.59 beat InflaRx's score of 0.00 indicating that Editas Medicine is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
InflaRx
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Editas Medicine
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

InflaRx has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.15, suggesting that its share price is 115% more volatile than the S&P 500.

InflaRx currently has a consensus price target of $6.60, indicating a potential upside of 653.51%. Editas Medicine has a consensus price target of $4.70, indicating a potential upside of 64.34%. Given InflaRx's stronger consensus rating and higher possible upside, equities analysts plainly believe InflaRx is more favorable than Editas Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InflaRx
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Editas Medicine
2 Sell rating(s)
7 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
2.31

42.4% of InflaRx shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 16.3% of InflaRx shares are held by insiders. Comparatively, 1.9% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

InflaRx beats Editas Medicine on 10 of the 16 factors compared between the two stocks.

Get InflaRx News Delivered to You Automatically

Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IFRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IFRX vs. The Competition

MetricInflaRxMED IndustryMedical SectorNASDAQ Exchange
Market Cap$55.05M$2.87B$5.50B$8.95B
Dividend YieldN/A2.45%5.25%4.04%
P/E Ratio-1.0720.8026.9720.11
Price / Sales326.66286.31425.92119.81
Price / CashN/A41.1936.8257.86
Price / Book0.787.487.985.56
Net Income-$49.85M-$55.04M$3.16B$248.40M
7 Day Performance8.00%2.44%2.36%4.67%
1 Month Performance3.05%1.90%2.15%6.64%
1 Year Performance-47.55%4.35%33.78%21.31%

InflaRx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IFRX
InflaRx
2.692 of 5 stars
$0.88
+6.8%
$6.60
+653.5%
-44.2%$55.05M$180K-1.0760
EDIT
Editas Medicine
4.1755 of 5 stars
$2.54
-1.2%
$4.70
+85.0%
-40.7%$215.14M$32.31M-0.84230
DSGN
Design Therapeutics
0.3745 of 5 stars
$3.54
-6.1%
$4.00
+13.0%
+4.0%$214.02MN/A-3.5840Positive News
TVRD
Tvardi Therapeutics
N/A$21.52
-4.2%
$71.50
+232.2%
N/A$210.25M$7.14M0.0080
SCPH
scPharmaceuticals
4.1364 of 5 stars
$3.86
-2.8%
$14.00
+262.7%
-9.4%$209.58M$36.33M-2.0230
MDWD
MediWound
1.619 of 5 stars
$19.27
-0.4%
$31.80
+65.0%
+0.1%$209.02M$20.22M-9.2280
KOD
Kodiak Sciences
4.1301 of 5 stars
$3.71
-6.1%
$9.00
+142.6%
+58.5%$208.42MN/A-1.0290News Coverage
ACIU
AC Immune
2.7562 of 5 stars
$1.99
-3.9%
$12.00
+503.0%
-40.5%$207.85M$31.02M-3.43140
CRGX
CARGO Therapeutics
2.1148 of 5 stars
$4.39
-1.6%
$15.00
+241.7%
-71.4%$205.65MN/A-0.95116Trending News
Analyst Forecast
Gap Up
LRMR
Larimar Therapeutics
1.9094 of 5 stars
$3.20
flat
$18.50
+478.1%
-59.5%$204.89MN/A-2.1530
CTMX
CytomX Therapeutics
3.9205 of 5 stars
$2.37
-5.2%
$5.33
+125.0%
+84.6%$201.55M$138.10M4.94170

Related Companies and Tools


This page (NASDAQ:IFRX) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners